“Patients with a self-administered nasal spray application found to have reduced S—S-C*V-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours. Trial concluded that treatment accelerated clearance of S—S-C*V-2 by a factor of 16-fold versus a placebo. Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of C*<iD-i9, the majority heavily-infected with the U |< v*riant. No adverse events were recorded in the group Submission for Emergency Use in the UK and Canada for the treatment and prevention of C*<iD-i9 is planned immediately”. #healthchoice #healthchoiceri #doubleblindplacebo #H5989 #H5706 #H5443 #informedconsent #bodilyautonomy #bodilysovereignty https://www.instagram.com/p/CN5K965H0lr/?igshid=h563840qv3s2
